Allergy Therapeutics PLC AGYTF reported a decline in its profit for the full year.
Allergy Therapeutics' pretax profit for the year slipped to 654,000 pounds ($1.0 million), versus GBP1.1 million in the year-ago period.
Its revenue increased to GBP43.2 million from GBP42.0 million.
CEO Manuel Llobet said, "Growth in the European markets is expected to be relatively slow in the coming year but with the continued momentum across the company's activities, the outlook is very positive and we expect to increase our market share into the next year, delivering improved top-line growth."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in